title: Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123.
abstract: OBJECTIVE
  To test the usefulness of single photon emission computed tomography (SPECT) with iodobenzamide in imaging basal ganglia and to elucidate the postulated upward regulation of the striatal D2 dopamine receptors in patients with early Parkinson's disease.
  
  
  METHODS
  Fourteen patients with Parkinson's disease and eight control subjects were investigated with SPECT using iodobenzamide labeled with iodine 123 as dopamine receptor ligand.
  
  
  METHODS
  Neurological outpatient service at a university hospital in Kuopio, Finland.
  
  
  METHODS
  Fourteen patients with recently diagnosed unilateral, unmedicated Parkinson's disease and eight healthy control subjects.
  
  
  RESULTS
  The SPECT images revealed high uptake of iodobenzamide in the basal ganglia. In the patient group, the accumulation was more intense and the iodobenzamide affinity rate was significantly higher in the striatum contralateral to the parkinsonian symptoms. Also, the basal ganglia-cerebellum ratio was higher in the contralateral hemisphere. In the control group, no significant side-to-side differences were observed.
  
  
  CONCLUSIONS
  Iodobenzamide with SPECT imaging is useful in evaluating patients with Parkinson's disease. The results also suggest compensatory D2 dopamine receptor upward regulation in the striatum of patients with early unmedicated Parkinson's disease.
authors: Department of Neurology, Kuopio University Hospital, Finland.
authors: V
authors: V
authors: Laulumaa
authors: J T
authors: JT
authors: Kuikka
authors: H
authors: H
authors: Soininen
authors: K
authors: K
authors: Bergström
authors: E
authors: E
authors: Länsimies
authors: P
authors: P
authors: Riekkinen
mesh_terms: D000368:Aged; D001549:Benzamides / Q000493:pharmacokinetics; D003342:Corpus Striatum / Q000737:chemistry / Q000378:metabolism*; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism*; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000737:chemistry / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D001549:Benzamides; D065127:Dopamine D2 Receptor Antagonists; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide